Meeting
2015 Genitourinary Cancers Symposium
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Guru Sonpavde
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL
Guru Sonpavde , Gregory Russell Pond , Arnoud J. Templeton , Daniel Peter Petrylak , Bertrand F. TOMBAL , Mark Rosenthal , Ian Tannock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 186)
DOI
10.1200/jco.2015.33.7_suppl.186
Abstract #
186
Poster Bd #
H22
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data.
First Author: Anish B. Parikh
Poster
2016 ASCO Annual Meeting
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
First Author: Johann S. De Bono
Poster
2016 Genitourinary Cancers Symposium
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.
First Author: Maria Agnese Fabbri
Poster
2015 ASCO Annual Meeting
Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Gregory Russell Pond